Clinical Trial Update: Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial update reports safety and preliminary efficacy of AZD7789 in patients with relapsed or refractory classical Hodgkin lymphoma. Results were posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classical Hodgkin Lymphoma

Drugs mentioned

• AZD7789

Snippet

Sponsor: AstraZeneca | Conditions: Relapsed or Refractory Classical Hodgkin Lymphoma | Phase 1 | Status: COMPLETED | Results posted: 2025-05-02